Houtai Choumane

TLDR

Houtai Choumane is founder and CEO of KiOmed Pharma, a Belgian biotech spin-off of Kitozyme developing medical devices and therapeutics based on KiOmedine, an animal-free chitosan biopolymer.

Overview

Dr. Houtai Choumane has led KiOmed Pharma as CEO and Managing Director since its founding in 2014. He brings nearly 20 years of experience in product development, executive management, and business development for innovative biotech companies. KiOmed Pharma is a spin-off from Kitozyme, a world-leading manufacturer of vegetable chitosan.

The company's core technology, KiOmedine, is an animal-free biodegradable biopolymer positioned as an alternative to hyaluronic acid for treating osteoarthritis. Its flagship product KioMedine-vs-one received approval from the Chinese FDA and the company has signed an exclusive partnership with Sinclair Pharma.